Literature DB >> 10525558

An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting.

M Rutten-van Mölken1, B Roos, J A Van Noord.   

Abstract

BACKGROUND: The Chronic Respiratory Questionnaire (CRQ) and the St George's Respiratory Questionnaire (SGRQ) are the two most widely used quality of life questionnaires in chronic obstructive pulmonary disease (COPD). A study was undertaken to compare directly the self-administered version of the CRQ and the SGRQ with respect to feasibility, internal consistency, validity, and sensitivity to changes resulting from bronchodilator therapy.
METHODS: One hundred and forty four patients with moderate or severe COPD were randomly assigned to receive three months of treatment with either salmeterol, salmeterol + ipratropium bromide, or placebo. Quality of life was measured at baseline and after 12 weeks of treatment.
RESULTS: The proportions of missing values per patient were low for both questionnaires (0.54% for the CRQ and 2% for the SGRQ). The internal consistency was good for both questionnaires (Cronbach's alpha coefficients >/= 0.84 for the CRQ and >/= 0.76 for the SGRQ). Factor analysis confirmed the original domain structure of the CRQ but not of the SGRQ. Correlations with forced expiratory volume in one second (FEV(1)) % predicted and peak expiratory flow rate (PEFR) were low for both questionnaires but better for the SGRQ than for the CRQ. The ability to discriminate between subjects with different levels of FEV(1) was somewhat better for the SGRQ. The correlations with symptom scores were comparable for both questionnaires. Cross sectionally, the scores of the two questionnaires were moderately to highly correlated (coefficients ranged from 0.35 to 0.72). Longitudinally, these correlations were lower (coefficients ranged from 0.17 to 0.54) but were still significant. The CRQ total and emotions score and the SGRQ symptoms score were the most responsive to change. The SGRQ symptoms domain was the only domain where the improvement in patients receiving combination treatment crossed the threshold for clinical relevance.
CONCLUSIONS: Since this analysis of reliability, validity, and responsiveness to change did not clearly favour one instrument above the other, the choice between the CRQ and the SGRQ can be based on other considerations such as the required sample size or the availability of reference values.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10525558      PMCID: PMC1745382          DOI: 10.1136/thx.54.11.995

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  25 in total

1.  Quality of life changes in COPD patients treated with salmeterol.

Authors:  P W Jones; T K Bosh
Journal:  Am J Respir Crit Care Med       Date:  1997-04       Impact factor: 21.405

2.  Measurement of health status. Ascertaining the minimal clinically important difference.

Authors:  R Jaeschke; J Singer; G H Guyatt
Journal:  Control Clin Trials       Date:  1989-12

3.  Should study subjects see their previous responses: data from a randomized control trial.

Authors:  G H Guyatt; M Townsend; J L Keller; J Singer
Journal:  J Clin Epidemiol       Date:  1989       Impact factor: 6.437

4.  Home assessment of activities of daily living in patients with severe chronic obstructive pulmonary disease on long-term oxygen therapy.

Authors:  A A Okubadejo; L O'Shea; P W Jones; J A Wedzicha
Journal:  Eur Respir J       Date:  1997-07       Impact factor: 16.671

5.  A measure of quality of life for clinical trials in chronic lung disease.

Authors:  G H Guyatt; L B Berman; M Townsend; S O Pugsley; L W Chambers
Journal:  Thorax       Date:  1987-10       Impact factor: 9.139

6.  Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting.

Authors:  R Harper; J E Brazier; J C Waterhouse; S J Walters; N M Jones; P Howard
Journal:  Thorax       Date:  1997-10       Impact factor: 9.139

7.  Comparison of discriminative properties among disease-specific questionnaires for measuring health-related quality of life in patients with chronic obstructive pulmonary disease.

Authors:  T Hajiro; K Nishimura; M Tsukino; A Ikeda; H Koyama; T Izumi
Journal:  Am J Respir Crit Care Med       Date:  1998-03       Impact factor: 21.405

8.  Clinical impact versus factor analysis for quality of life questionnaire construction.

Authors:  E F Juniper; G H Guyatt; D L Streiner; D R King
Journal:  J Clin Epidemiol       Date:  1997-03       Impact factor: 6.437

9.  Long-term outcome of pulmonary rehabilitation in patients with COPD.

Authors:  C A Ketelaars; H H Abu-Saad; M A Schlösser; R Mostert; E F Wouters
Journal:  Chest       Date:  1997-08       Impact factor: 9.410

10.  Domiciliary liquid oxygen versus concentrator treatment in chronic hypoxaemia: a cost-utility analysis.

Authors:  A Andersson; K Ström; H Brodin; M Alton; G Boman; P Jakobsson; A Lindberg; M Uddenfeldt; H Walter; L A Levin
Journal:  Eur Respir J       Date:  1998-12       Impact factor: 16.671

View more
  47 in total

1.  Outcomes in Cardiopulmonary Physical Therapy: Chronic Respiratory Disease Questionnaire (CRQ).

Authors:  Alyssa Chauvin; Laurel Rupley; Katie Meyers; Kristin Johnson; Jane Eason
Journal:  Cardiopulm Phys Ther J       Date:  2008-06

2.  Outcomes in cardiopulmonary physical therapy: sickness impact profile.

Authors:  Sheronda Bowers; Katie Cannizzaro; Jessica Gregus; Quanteria Scott; Jane Eason
Journal:  Cardiopulm Phys Ther J       Date:  2009-03

Review 3.  Health status measurement in chronic obstructive pulmonary disease.

Authors:  P W Jones
Journal:  Thorax       Date:  2001-11       Impact factor: 9.139

4.  Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD.

Authors:  Shelley R Salpeter; Nicholas S Buckley; Edwin E Salpeter
Journal:  J Gen Intern Med       Date:  2006-10       Impact factor: 5.128

Review 5.  Assessment of progression of COPD: report of a workshop held in Leuven, 11-12 March 2004.

Authors:  M Decramer; R Gosselink; M Rutten-Van Mölken; J Buffels; O Van Schayck; P-A Gevenois; R Pellegrino; E Derom; W De Backer
Journal:  Thorax       Date:  2005-04       Impact factor: 9.139

6.  Health-related quality of life in asthma: a comparison between the St George's Respiratory Questionnaire and the Asthma Quality of Life Questionnaire.

Authors:  Carlos Sanjuás; Jordi Alonso; Luis Prieto; Montse Ferrer; Joan M Broquetas; Josep M Antó
Journal:  Qual Life Res       Date:  2002-12       Impact factor: 4.147

7.  Utility estimation in chronic obstructive pulmonary disease: a preference for change?

Authors:  Jennifer Petrillo; Floortje van Nooten; Paul Jones; Maureen Rutten-van Mölken
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

8.  Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD.

Authors:  V Brusasco; R Hodder; M Miravitlles; L Korducki; L Towse; S Kesten
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

Review 9.  A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease.

Authors:  Milind P Sovani; Christopher I Whale; Anne E Tattersfield
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

10.  Validity, reliability, and responsiveness of a new short Visual Simplified Respiratory Questionnaire (VSRQ) for health-related quality of life assessment in chronic obstructive pulmonary disease.

Authors:  T Perez; B Arnould; J-M Grosbois; V Bosch; I Guillemin; M-L Bravo; M Brun; A-B Tonnel
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.